1.35 USD
↗ 0.00 (0.00%)LIVE (AS OF 09:35 AM EDT)
Calidi Biotherapeutics, Inc.
CLDIAMEX • USD
Market: OPEN
Calidi Biotherapeutics, Inc. (CLDI) trades at $1.35 per share. Both sides of the analysis point lower: technicals flash "Sell" and fundamentals confirm with a "Sell" reading. Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.
Technical & fundamental data as of Aug 26, 2026.
Open?$1.36
High?$1.36
Low?$1.31
Prev. Close?$1.35
Volume?28.9K
Avg. Volume?4.2M
VWAP?$1.33
Rel. Volume?0.01x
Bid / Ask
Bid?$1.31 × 4.0K
Ask?$1.37 × 100
Spread?$0.06
Midpoint?$1.34
Valuation & Ratios
Market Cap?3.5M
Shares Out?2.6M
Float?18.4M
Float %?95.5%
P/E Ratio?N/A
P/B Ratio?1.11
EPS?-$9.08
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.
Themes
Employees
29
Market Cap
3.5M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2023-09-13
Address
4475 EXECUTIVE DRIVE
SAN DIEGO, CA 92121
Phone: 858-794-9600
SAN DIEGO, CA 92121
Phone: 858-794-9600
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?0
Momentum?50
Short Sent.?74
Piotroski F-Score?0/9Weak
Altman Z-Score?-36.43Distress
Confidence?45%Low
Short InterestLow
Short % of Float?1.70%Low
Short Interest?313.3K
Days to Cover?1.6
Free Float18.4M
Avg Daily Volume201.6K
Settlement Date2026-08-14
Financial Health
Current Ratio?1.68Adequate
Quick Ratio?1.68Adequate
Cash Ratio?1.26Strong
Debt/Equity?0.30Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?1.11CHEAP▾
Peers100
S&P95
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-0.0CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-748.6%WEAK▾
S&P3
ROA?-325.6%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-17845000
Enterprise Value?$345.6K
Fundamentals ratios updated end of day